Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA

Michele B. Kaufman, PharmD, BCGP  |  Issue: November 2020  |  October 9, 2020

In late September, the U.S. Food & Dug Administration (FDA) approved tofacitinib (Xeljanz) to treat patients 2 years and older with active polyarticular juvenile idiopathic arthritis (pJIA). This treatment is the first and only Janus kinase inhibitor (jakinib) approved in the U.S. for this indication.1

The drug is already available in 5 mg tablets and will also be made available as an oral solution by the end of the first quarter of 2021.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA approval was based on a phase 3 safety and efficacy study that had two phases over 44 weeks. The study’s first phase was an 18-week, open-label, run-in phase that included 225 patients who received tofacitinib. It was followed by a 26-week, double-blind, randomized, placebo-controlled withdrawal phase that included 173 patients.

In the first phase, patients received a 5 mg tablet or a 1 mg/mL dose of tofacitinib oral solution, or placebo twice daily. If patients weighed less than 40 kg or had a preference for the solution, they received the oral solution. The study’s primary endpoint at the end of the first phase was the achievement of a JIA ACR30 response—an improvement of 30% from baseline in three of six variables (i.e., physician global assessment of disease activity, parent/guardian’s or patient’s global assessment of overall well-being, functional ability, number of joints with active arthritis, number of joints with limited range of motion and erythrocyte sedimentation rate) and no more than one of the remaining variables worsening by more than 30%.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The trial met its primary endpoint. At week 44—the end of the second phase—the tofacitinib-treated patients who achieved a JIA ACR30 response at the end of the study’s first phase had a statistically significant lower occurrence of disease flare (31%) than placebo-treated patients (55%; P=0.0007). In this study, disease flare was defined as a 30% or greater worsening in at least three of the six variables of the JIA ACR core set, with no more than one of the remaining JIA core response variables improving by at least 30% (outcome measures used in JIA clinical trials) after randomization.

Generally, adverse reactions in pJIA patients were consistent with those seen in adult patients with rheumatoid arthritis.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

  1. Pfizer Inc. News release: U.S. FDA approves Pfizer’s Xeljanz (tofacitinib) for the treatment of active polyarticular course juvenile idiopathic arthritis. 2020 Sep 28.

Page: 1 2 | Multi-Page
Share: 

Filed under:Drug Updates Tagged with:FDApolyarticular juvenile idiopathic arthritis (JIA)TofacitinibU.S. Food and Drug Administration (FDA)

Related Articles

    EU Approves Tofacitinib Citrate for 2 Pediatric Conditions

    September 8, 2021

    The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.

    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    What Adult Rheumatologists Need to Know about Juvenile Arthritis

    May 1, 2013

    How to recognize distinctions between pediatric and adult arthritis

    Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

    July 13, 2017

    Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences